SCHEMBL1395935

SCHEMBL1395935

[c]1[c]c2nc3ccccc3nc2cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
NQO2 P16083 6/20 0.39
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
NPC1 O15118 2/20 0.37
POLB P06746 2/20 0.37
USP2 O75604 1/20 0.37
CACNA1B Q00975 1/20 0.37
APBA1 Q02410 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ALDH1A1 P00352 6/20 0.36
HPGD P15428 3/20 0.36
KDM4E B2RXH2 3/20 0.36
GAA P10253 2/20 0.36
GLA P06280 2/20 0.36
ACHE P22303 2/20 0.36
HSD17B10 Q99714 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
RAB9A P51151 3/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25712 0.73 MAPT (0.52) MAPTNQO2KMT2AMEN1NPC1
SCHEMBL752521 0.69 ALDH1A1 (0.52) MAPTNQO2KMT2ANPC1POLB
Phenazine SCHEMBL27643128 0.69 MAPT (1.00) MAPTNQO2KMT2AMEN1NPC1
Phenazine SCHEMBL29356959 0.69 MAPT (1.00) MAPTNQO2KMT2AMEN1NPC1
Phenazine SCHEMBL9049 0.69 MAPT (1.00) MAPTNQO2KMT2AMEN1NPC1
Phenazine SCHEMBL3119916 0.66 MAPT (0.92) MAPTNQO2KMT2AMEN1NPC1
Phenazine SCHEMBL22345160 0.66 MAPT (0.92) MAPTNQO2KMT2AMEN1NPC1
Phenazine SCHEMBL20475337 0.66 MAPT (0.92) MAPTNQO2KMT2AMEN1NPC1
Phenazine SCHEMBL20475326 0.66 MAPT (0.92) MAPTNQO2KMT2AMEN1NPC1
Phenazine SCHEMBL10866237 0.66 MAPT (0.92) MAPTNQO2KMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6946207-B2 Electroconductive device, organic electroluminescence device using the device and process for producing the electroconductive device CANON KABUSHIKI KAISHA (JP) 2005-09-20 US claimed
US-20020135292-A1 Electroconductive device, organic electroluminescence device using the device and process for producing the electroconductive device CANON KABUSHIKI KAISHA (JP) 2002-09-26 US claimed
CN-118076602-A Heteroaryl-acetylenes, pharmaceutical compositions thereof and their therapeutic uses 嘉兴优博生物技术有限公司 2024-05-24 CN disclosed
EP-3751631-B1 POLYMER MATERIAL, MATERIAL FOR ELECTROLUMINESCENCE DEVICE, LIQUID COMPOSITION, THIN FILM, AND ELECTROLUMINESCENCE DEVICE SAMSUNG ELECTRONICS CO LTD (KR) 2023-12-13 EP disclosed
CN-117203196-A PDE4 degrading agents, pharmaceutical compositions and therapeutic applications 拜欧斯瑞克斯公司 2023-12-08 CN disclosed
US-11771695-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2023-10-03 US disclosed
US-11746091-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2023-09-05 US disclosed
US-20220241274-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2022-08-04 US disclosed
CN-109970708-B Cannabinoid receptor modulators 艾尼纳制药公司 2022-06-21 CN disclosed
US-11214548-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2022-01-04 US disclosed
US-20210188781-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2021-06-24 US disclosed
US-6960364-B2 Organic electroluminescent element and its manufacturing method KONICA CORPORATION (JP) 2005-11-01 US disclosed
US-6946207-B2 Electroconductive device, organic electroluminescence device using the device and process for producing the electroconductive device CANON KABUSHIKI KAISHA (JP) 2005-09-20 US disclosed
US-20040126616-A1 Polyester resin, functional device and organic electroluminescent device using polyester resin, and method of manufacturing organic electroluminescent device FUJI XEROX CO., LTD (JP) 2004-07-01 US disclosed
US-20040005404-A1 Organic electroluminescent element and its manufacturing method MERCK PATENT GMBH (DE) 2004-01-08 US disclosed
EP-1371709-A1 Organic electroluminescent element and its manufacturing method KONICA CORPORATION (JP) 2003-12-17 EP disclosed
US-20020135292-A1 Electroconductive device, organic electroluminescence device using the device and process for producing the electroconductive device CANON KABUSHIKI KAISHA (JP) 2002-09-26 US disclosed
EP-1174430-A1 Process for the preparation of heterocycles by using C1-building blocks Universität Konstanz (DE) 2002-01-23 EP disclosed
US-6051722-A PRECURSOR FOR POLYIMIDE COPOLYMER; USABLE IN OPTICAL LONG-DISTANCE COMMUNICATION, SIGNAL PROCESSING, PHOTOELECTRIC HYBRID CIRCUITS AND OPTICAL COMPUTERS HITACHI CHEMICAL COMPANY, LTD. (JP) 2000-04-18 US disclosed
US-5834575-A POLYIMIDE OR POLYACRYLATE WITH PENDANT GROUP CONTAINING THIOPHENE RING, BENZENE RING AND VICINAL NITRILE GROUPS, SWITCHES FOR OPTICAL SIGNALS, COMMUNICATION TECHNOLOGY HITACHI CHEMICAL COMPANY, LTD. (JP) 1998-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11746091-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 MAPT 627/4885NQO2 4264/4885KMT2A 2962/4885
US-11214548-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 MAPT 627/4885NQO2 4264/4885KMT2A 2962/4885
US-20220241274-A1 CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, OPRL1 MAPT 3271/4885NQO2 2680/4885KMT2A 2956/4885
US-20210188781-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 MAPT 627/4885NQO2 4264/4885KMT2A 2962/4885
US-11771695-B2 Cannabinoid receptor modulators CNR2, CNR1, OPRL1 MAPT 3271/4885NQO2 2680/4885KMT2A 2956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.